AstraZeneca Drug Trial Failure Has Major Implications To Its Pipeline
October 04, 2016 at 10:14 AM EDT
AstraZeneca plc (ADR) (NYSE: AZN) announced that its anti-platelet drug, Brilinta, had failed to meet the primary end point in the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.